Aneurysmal subarachnoid hemorrhage (aSAH) is a type of hemorrhagic stroke that can cause significant morbidity and mortality. Although guidelines have been published to help direct the care of these patients, there is insufficient quality literature regarding the medical and pharmacological management of patients with aSAH. Treatment is divided into 3 categories: supportive therapy, prevention of complications, and treatment of complications. There are numerous pharmacological therapies that are targeted at prevention and treatment of the neurological and medical complications that may arise. Rebleeding, hydrocephalus, cerebral vasospasm, and seizures are the most common neurological complications while the most common medical complications include hyponatremia, pulmonary edema, cardiac arrhythmias, neurogenic stunned myocardium, fever, anemia, infection, hyperglycemia, and venous thromboembolism. Risk factors, clinical presentation, diagnosis, pathophysiology, as well as initial management, prevention, and treatment of complications will be the focus of this discussion.
LinnFHRinkelGJAlgraA. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography: a meta-analysis. Stroke. 1996;27(4):625–629.
2.
HuangJvan GelderJM. The probability of sudden death from rupture of intracranial aneurysms: a meta-analysis. Neurosurgery. 2002;51(5):1101–1105;.discussion 1105-1107.
3.
MayerSAKreiterKTCopelandD. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology. 2002;59(11):1750–1758.
4.
BedersonJBConnollyESJrBatjerHH. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40(3):994–1025.
5.
LindsayKWTeasdaleGMKnill-JonesRP. Observer variability in assessing the clinical features of subarachnoid hemorrhage. J Neurosurg. 1983;58(1):57–62.
6.
BroderickJPBrottTTomsickT. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med. 1992;326(11):733–736.
7.
BroderickJPViscoliCMBrottT. Major risk factors for aneurysmal subarachnoid hemorrhage in the young are modifiable. Stroke. 2003;34(6):1375–1381.
8.
QureshiAISuriMFYahiaAM. Risk factors for subarachnoid hemorrhage. Neurosurgery. 2001;49(3):607–612; discussion 12-13.
9.
PopeFMNichollsACNarcisiP. Some patients with cerebral aneurysms are deficient in type III collagen. Lancet. 1981;1(8227):973–975.
10.
van GijnJKerrRSRinkelGJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306–318.
11.
WhitePMWardlawJ. Unruptured intracranial aneurysms: prospective data have arrived. Lancet. 2003;362(9378):90–91.
12.
WiebersDOWhisnantJPHustonJIII. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103–110.
13.
AndersonCNi MhurchuCScottD. Triggers of subarachnoid hemorrhage: role of physical exertion, smoking, and alcohol in the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). Stroke. 2003;34(7):1771–1776.
14.
FannJRKukullWAKatonWJ. Physical activity and subarachnoid haemorrhage: a population based case-control study. J Neurol Neurosurg Psychiatry. 2000;69(6):768–772.
15.
KoliasAGSenJBelliA. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. J Neurosci Res. 2009;87(1):1–11.
16.
LinnFHRinkelGJAlgraA. Headache characteristics in subarachnoid haemorrhage and benign thunderclap headache. J Neurol Neurosurg Psychiatry. 1998;65(5):791–793.
17.
WagaSOtsuboKHandaH. Warning signs in intracranial aneurysms. Surg Neurol. 1975;3(1):15–20.
18.
RhoneyDHTippsLBMurryKR. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology. 2000;55(2):258–265.
19.
HartRGByerJASlaughterJR. Occurrence and implications of seizures in subarachnoid hemorrhage due to ruptured intracranial aneurysms. Neurosurgery. 1981;8(4):417–421.
20.
van der WeeNRinkelGJHasanD. Detection of subarachnoid haemorrhage on early CT: is lumbar puncture still needed after a negative scan?J Neurol Neurosurg Psychiatry. 1995;58(3):357–359.
21.
PierotLAggourMMoretJ. Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management. Curr Opin Crit Care. 2010;16(2):110–116.
22.
BoesigerBMShiberJR. Subarachnoid hemorrhage diagnosis by computed tomography and lumbar puncture: are fifth generation CT scanners better at identifying subarachnoid hemorrhage?J Emerg Med. 2005;29(1):23–27.
23.
O'NeillJMcLagganSGibsonR. Acute headache and subarachnoid haemorrhage: a retrospective review of CT and lumbar puncture findings. Scott Med J. 2005;50(4):151–153.
24.
van GijnJRinkelGJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain. 2001;124(pt 2):249–278.
25.
SehbaFABedersonJB. Mechanisms of acute brain injury after subarachnoid hemorrhage. Neurol Res. 2006;28(4):381–398.
26.
HuntWEHessRM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968;28(1):14–20.
27.
TakagiKTamuraANakagomiT. How should a subarachnoid hemorrhage grading scale be determined? A combinatorial approach based solely on the Glasgow Coma Scale. J Neurosurg. 1999;90(4):680–687.
28.
FronteraJAClaassenJSchmidtJM. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery. 2006;59(1):21–27; discussion 21-27.
29.
SederDBMayerSA. Critical care management of subarachnoid hemorrhage and ischemic stroke. Clin Chest Med. 2009;30(1):103–122, viii-ix.
30.
WartenbergKESchmidtJMClaassenJ. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med. 2006;34(3):617–623; quiz 624.
31.
SpringerMVSchmidtJMWartenbergKE. Predictors of global cognitive impairment 1 year after subarachnoid hemorrhage. Neurosurgery. 2009;65(6):1043–1050; discussion 50-51.
32.
LocksleyHB. Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. J Neurosurg. 1966;25(3):321–368.
33.
KassellNFTornerJC. Aneurysmal rebleeding: a preliminary report from the Cooperative Aneurysm Study. Neurosurgery. 1983;13(5):479–481.
34.
SheehanJPPolinRSSheehanJM. Factors associated with hydrocephalus after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1999;45(5):1120–1127; discussion 1127-1128.
35.
HasanDVermeulenMWijdicksEF. Management problems in acute hydrocephalus after subarachnoid hemorrhage. Stroke. 1989;20(6):747–753.
36.
LevineJM. Critical care management of subarachnoid hemorrhage. Curr Neurol Neurosci Rep. 2008;8(6):518–525.
37.
HarrodCGBendokBRBatjerHH. Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery. 2005;56(4):633–654; discussion 633-654.
MacdonaldRLRosengartAHuoD. Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99(4):644–652.
40.
LinCLDumontASLieuAS. Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99(6):978–985.
41.
ClaassenJPeerySKreiterKT. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Neurology. 2003;60(2):208–214.
42.
DennisLJClaassenJHirschLJ. Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery. 2002;51(5):1136–1143; discussion 1144.
43.
NaidechAMKreiterKTJanjuaN. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36(3):583–587.
44.
ChumnanvejSDunnIFKimDH. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007;60(1):99–102; discussion 102-103.
45.
McKhannGM IILe RouxPD. Perioperative and intensive care unit care of patients with aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am. 1998;9(3):595–613.
46.
KopelnikAZaroffJG. Neurocardiogenic injury in neurovascular disorders. Crit Care Clin. 2006;22(4):733–752; abstract ix-x.
47.
AndreoliAdi PasqualeGPinelliG. Subarachnoid hemorrhage: frequency and severity of cardiac arrhythmias. A survey of 70 cases studied in the acute phase. Stroke. 1987;18(3):558–564.
48.
KothavaleABankiNMKopelnikA. Predictors of left ventricular regional wall motion abnormalities after subarachnoid hemorrhage. Neurocrit Care. 2006;4(3):199–205.
49.
TungPKopelnikABankiN. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. Stroke. 2004;35(2):548–551.
50.
CragoEAKerrMEKongY. The impact of cardiac complications on outcome in the SAH population. Acta Neurol Scand. 2004;110(4):248–253.
51.
LagerkranserMPehrssonKSylvenC. Neurogenic pulmonary oedema. A review of the pathophysiology with clinical and therapeutic implications. Acta Med Scand. 1982;212(4):267–271.
52.
OropelloJMWeinerLBenjaminE. Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage. Is it efficacious? No. Crit Care Clin. 1996;12(3):709–730.
53.
KruytNDBiesselsGJde HaanRJ. Hyperglycemia and clinical outcome in aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke. 2009;40(6):e424–e430.
54.
FronteraJAFernandezAClaassenJ. Hyperglycemia after SAH: predictors, associated complications, and impact on outcome. Stroke. 2006;37(1):199–203.
55.
BadjatiaNTopcuogluMABuonannoFS. Relationship between hyperglycemia and symptomatic vasospasm after subarachnoid hemorrhage. Crit Care Med. 2005;33(7):1603–1609; quiz 1623.
56.
SchlenkFVajkoczyPSarrafzadehA. Inpatient hyperglycemia following aneurysmal subarachnoid hemorrhage: relation to cerebral metabolism and outcome. Neurocrit Care. 2009;11(1):56–63.
57.
VespaPBoonyaputthikulRMcArthurDL. Intensive insulin therapy reduces microdialysis glucose values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury. Crit Care Med. 2006;34(3):850–856.
58.
OddoMSchmidtJMCarreraE. Impact of tight glycemic control on cerebral glucose metabolism after severe brain injury: a microdialysis study. Crit Care Med. 2008;36(12):3233–3238.
59.
YoderJ. Con: tight glucose control after brain injury is unproven and unsafe. J Neurosurg Anesthesiol. 2009;21(1):55–57.
60.
EgiMBellomoRReadeMC. Is reducing variability of blood glucose the real but hidden target of intensive insulin therapy?Crit Care. 2009;13(2):302.
61.
RayWZStromRGBlackburnSL. Incidence of deep venous thrombosis after subarachnoid hemorrhage. J Neurosurg. 2009;110(5):1010–1014.
62.
KimKSBrophyGM. Symptomatic venous thromboembolism: incidence and risk factors in patients with spontaneous or traumatic intracranial hemorrhage. Neurocrit Care. 2009;11(1):28–33.
63.
GeertsWHBergqvistDPineoGF. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S–453S.
64.
NorwoodSHMcAuleyCEBerneJD. Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. Arch Surg. 2002;137(6):696–701; discussion 701-702.
65.
VergouwenMDRoosYBKamphuisenPW. Venous thromboembolism prophylaxis and treatment in patients with acute stroke and traumatic brain injury. Curr Opin Crit Care. 2008;14(2):149–155.
66.
NaidechAMBendokBRBernsteinRA. Fever burden and functional recovery after subarachnoid hemorrhage. Neurosurgery. 2008;63(2):212–217; discussion 217-218.
67.
Oliveira-FilhoJEzzeddineMASegalAZ. Fever in subarachnoid hemorrhage: relationship to vasospasm and outcome. Neurology. 2001;56(10):1299–1304.
68.
FernandezASchmidtJMClaassenJ. Fever after subarachnoid hemorrhage: risk factors and impact on outcome. Neurology. 2007;68(13):1013–1019.
69.
KramerAHZygunDABleckTP. Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;10(2):157–165.
70.
SampsonTRDharRDiringerMN. Factors associated with the development of anemia after subarachnoid hemorrhage. Neurocrit Care. 2010;12(1):4–9.
71.
KramerAHGurkaMJNathanB. Complications associated with anemia and blood transfusion in patients with aneurysmal subarachnoid hemorrhage. Crit Care Med. 2008;36(7):2070–2075.
72.
MirskiMALewinJJLedrouxS. Preservation of cognition during ICU sedation—the Johns Hopkins Acute Neurological ICU Sedation Trial (ANIST) [Abstract]. Crit Care Med. 2008;36:A10.
73.
WartenbergKEMayerSA. Medical complications after subarachnoid hemorrhage: new strategies for prevention and management. Curr Opin Crit Care. 2006;12(2):78–84.
74.
MolyneuxAKerrRStrattonI. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet. 2002;360(9342):1267–1274.
75.
MayerSASchwabS. Advances in critical care and emergency medicine. Stroke. 2010;41(2):e74–e76.
76.
MolyneuxAJKerrRSYuLM. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366(9488):809–817.
77.
MolyneuxAJKerrRSBirksJ. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. Lancet Neurol. 2009;8(5):427–433.
78.
RoosY. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology. 2000;54(1):77–82.
79.
VermeulenMLindsayKWMurrayGD. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med. 1984;311(7):432–437.
80.
HillmanJFridrikssonSNilssonO. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg. 2002;97(4):771–778.
81.
StarkeRMKimGHFernandezA. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke. 2008;39(9):2617–2621.
82.
RhoneyDHLiu-DeRykeX. Effect of vasoactive therapy on cerebral circulation. Crit Care Clin. 2006;22(2):221–243, vi.
83.
WijdicksEFVermeulenMMurrayGD. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 1990;92(2):111–117.
84.
ClaassenJVuAKreiterKT. Effect of acute physiologic derangements on outcome after subarachnoid hemorrhage. Crit Care Med. 2004;32(3):832–838.
85.
OhkumaHTsurutaniHSuzukiS. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke. 2001;32(5):1176–1180.
86.
Liu-DerykeXJanisseJCoplinWM. A comparison of nicardipine and labetalol for acute hypertension management following stroke. Neurocrit Care. 2008;9(2):167–176.
87.
DeeksEDKeatingGMKeamSJ. Clevidipine: a review of its use in the management of acute hypertension. Am J Cardiovasc Drugs. 2009;9(2):117–134.
88.
RhoneyDPeacockWF. Intravenous therapy for hypertensive emergencies, part 2. Am J Health Syst Pharm. 2009;66(16):1448–1457.
89.
RhoneyDPeacockWF. Intravenous therapy for hypertensive emergencies, part 1. Am J Health Syst Pharm. 2009;66(15):1343–1352.
90.
RoitbergBZHardmanJUrbaniakK. Prospective randomized comparison of safety and efficacy of nicardipine and nitroprusside drip for control of hypertension in the neurosurgical intensive care unit. Neurosurgery. 2008;63(1):115–120; discussion 120-121.
91.
NarotamPKPuriVRobertsJM. Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. J Neurosurg. 2008;109(6):1065–1074.
KarinenPKoivukangasPOhinmaaA. Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery. Neurosurgery. 1999;45(4):780–784; discussion 784-785.
94.
HaleyECJrKassellNFTornerJC. A randomized trial of nicardipine in subarachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78(4):548–553.
95.
HaleyECJrKassellNFTornerJC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78(4):537–547.
96.
BarthMCapelleHHWeidauerS. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke. 2007;38(2):330–336.
97.
KasuyaHOndaHSasaharaA. Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery. 2005;56(5):895–902; discussion 895-902.
98.
Amin-HanjaniSOgilvyCSBarkerFGII. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery. 2004;54(2):326–334; discussion 334-335.
99.
TreggiariMMWalderBSuterPM. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg. 2003;98(5):978–984.
100.
EggeAWaterlooKSjoholmH. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery. 2001;49(3):593–605; discussion 605-606.
101.
LennihanLMayerSAFinkME. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31(2):383–391.
102.
McGirtMJLynchJRParraA. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke. 2002;33(12):2950–2956.
103.
McGirtMJPradillaGLegnaniFG. Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery. 2006;58(5):945–951; discussion 945-951.
104.
O'DriscollGGreenDTaylorRR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95(5):1126–1131.
105.
SugawaraTAyerRJadhavV. Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. J Neurosci Res. 2008;86(16):3635–3643.
106.
VergouwenMDde HaanRJVermeulenM. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke. 2010;41(1):e47–e52.
107.
KramerAHFletcherJJ. Statins in the management of patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care. 2010;12(2):285–296.
108.
MoskowitzSIAhrensCProvencioJJ. Prehemorrhage statin use and the risk of vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2009;71(3):311–317; discussion 317-318.
109.
EndresMLaufsU. Effects of statins on endothelium and signaling mechanisms. Stroke. 2004;35(11 suppl 1):2708–2711.
110.
RisseladaRStraatmanHvan KootenF. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke. 2009;40(8):2887–2892.
111.
SinghalABTopcuogluMADorerDJ. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology. 2005;64(6):1008–1013.
112.
EsenFErdemTAktanD. Effect of magnesium sulfate administration on blood-brain barrier in a rat model of intraperitoneal sepsis: a randomized controlled experimental study. Crit Care. 2005;9(1):R18–R23.
113.
LudbrookGLJamesMFUptonRN. The effect of magnesium sulfate on cerebral blood flow velocity, cardiovascular variables, and arterial carbon dioxide tension in awake sheep. J Neurosurg Anesthesiol. 1999;11(2):96–101.
114.
MacdonaldRLCurryDJAiharaY. Magnesium and experimental vasospasm. J Neurosurg. 2004;100(1):106–110.
115.
PyneGJCadoux-HudsonTAClarkJF. Magnesium protection against in vitro cerebral vasospasm after subarachnoid haemorrhage. Br J Neurosurg. 2001;15(5):409–415.
116.
van den BerghWMAlgraAvan KootenF. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36(5):1011–1015.
117.
BoetRMeeE. Magnesium sulfate in the management of patients with Fisher Grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery. 2000;47(3):602–606; discussion 606-607.
118.
BarileMvan De WyngaertFMbiaJJ. Intravenous magnesium sulfate administration in a patient with refractory vasospasm following subarachnoid hemorrhage. Intensive Care Med. 2003;29(7):1182–1185.
119.
ChiaRYHughesRSMorganMK. Magnesium: a useful adjunct in the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. J Clin Neurosci. 2002;9(3):279–281.
120.
BrewerRPParraALynchJ. Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2001;13(3):202–206.
WongGKChanMTBoetR. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol. 2006;18(2):142–148.
123.
ZhaoXDZhouYTZhangX. A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate. J Clin Neurosci. 2009;16(11):1394–1397.
124.
KastnerSOertelMFScharbrodtW. Endothelin-1 in plasma, cisternal CSF and microdialysate following aneurysmal SAH. Acta Neurochir (Wien). 2005;147(12):1271–1279; discussion 1279.
125.
MacdonaldRLKassellNFMayerS. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015–3021.
126.
SuarezJIQureshiAIYahiaAB. Symptomatic vasospasm diagnosis after subarachnoid hemorrhage: evaluation of transcranial Doppler ultrasound and cerebral angiography as related to compromised vascular distribution. Crit Care Med. 2002;30(6):1348–1355.
127.
MannoEMGressDRSchwammLH. Effects of induced hypertension on transcranial Doppler ultrasound velocities in patients after subarachnoid hemorrhage. Stroke. 1998;29(2):422–428.
128.
EkelundASavelandHRomnerB. Is transcranial Doppler sonography useful in detecting late cerebral ischaemia after aneurysmal subarachnoid haemorrhage?Br J Neurosurg. 1996;10(1):19–25.
129.
CloftHJJosephGJDionJE. Risk of cerebral angiography in patients with subarachnoid hemorrhage, cerebral aneurysm, and arteriovenous malformation: a meta-analysis. Stroke. 1999;30(2):317–320.
130.
JanardhanVBiondiARiinaHA. Vasospasm in aneurysmal subarachnoid hemorrhage: diagnosis, prevention, and management. Neuroimaging Clin N Am. 2006;16(3):483–496, viii–ix.
131.
SolomonRAFinkMELennihanL. Early aneurysm surgery and prophylactic hypervolemic hypertensive therapy for the treatment of aneurysmal subarachnoid hemorrhage. Neurosurgery. 1988;23(6):699–704.
132.
JosephMZiadiSNatesJ. Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: a study using xenon computed tomographic measurement of cerebral blood flow. Neurosurgery. 2003;53(5):1044–1051; discussion 1051-1052.
133.
SolenskiNJHaleyECJrKassellNF. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med. 1995;23(6):1007–1017.
134.
NaidechADuYKreiterKT. Dobutamine versus milrinone after subarachnoid hemorrhage. Neurosurgery. 2005;56(1):21l–26l; discussion 26-72.
135.
KassellNFPeerlessSJDurwardQJ. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery. 1982;11(3):337–343.
136.
AwadIACarterLPSpetzlerRF. Clinical vasospasm after subarachnoid hemorrhage: response to hypervolemic hemodilution and arterial hypertension. Stroke. 1987;18(2):365–372.
137.
MuenchEHornPBauhufC. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. Crit Care Med. 2007;35(8):1844–1851; quiz 1852.
138.
FraticelliATCholleyBPLosserMR. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(3):893–898.
139.
BadjatiaNTopcuogluMAPryorJC. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol. 2004;25(5):819–826.
140.
KassellNFHelmGSimmonsN. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg. 1992;77(6):848–852.
141.
FengLFitzsimmonsBFYoungWL. Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. AJNR Am J Neuroradiol. 2002;23(8):1284–1290.
142.
TejadaJGTaylorRAUgurelMS. Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid hemorrhage-associated vasospasm: initial clinical experience with high-dose infusions. AJNR Am J Neuroradiol. 2007;28(5):844–848.
143.
McAuliffeWTownsendMEskridgeJM. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. J Neurosurg. 1995;83(3):430–434.
144.
HigashidaRTHalbachVVDowdCF. Intravascular balloon dilatation therapy for intracranial arterial vasospasm: patient selection, technique, and clinical results. Neurosurg Rev. 1992;15(2):89–95.
145.
GoodsonKLapointeMMonroeT. Intraventricular nicardipine for refractory cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care. 2008;8(2):247–252.
146.
RaabeAZimmermannMSetzerM. Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm. Neurosurgery. 2002;50(5):1006–1013; discussion 1013-1014.
147.
VajkoczyPHubnerUHornP. Intrathecal sodium nitroprusside improves cerebral blood flow and oxygenation in refractory cerebral vasospasm and ischemia in humans. Stroke. 2000;31(5):1195–1197.
